P1.06-002 Contralateral Axillary Lymph Node Metastasis of a Lung Cancer: A Case Report

Abstract

patients were not treated with TKIs, either because of poor performance status (40%), patient's refusal (30%), rapid disease progression (20%) or T790M mutation (10%). Conclusion: This study showed that incidence of molecular testing improved significantly over the course of the last years, leading to more effective targeted therapy. Overall survival was significantly prolonged in patients harboring an EGFR mutation treated with chemotherapy prior to TKIs, compared to patients without EGFR mutation treated only with conventional chemotherapy